

OK432

Size / Cat.No.: 100µg / GMP-TL107-0100

500µg / GMP-TL107-0500

Product Name

Generic Name OK432

Product Information

Activity	NK cells activated with this product have a cytotoxic index (T-C) of at least 15%
Formulation	lyophilized
Stability & Storage	Samples are stable for up to 24 months from date of receipt at 4 °C. Recommend to aliquot OK432 into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.

Background

OK432 is a freeze-dried devitalized bacterium. OK432-activated neutrophils could kill IFN- γ or TNF- α treated cancers cell. OK432 could induce neutrophil-killing effect on autologous tumor cells through CD11b/CD18 and ICAM-1 binding. OK432-induced monocytes are able to kill autologous tumor cells. After stimulation by OK432, lymphocytes shows fine LAK Cell activity and can even fight against anti-NK tumor cells.

References

1. Sakamoto N1,2, Ishikawa T3,4, Kokura S5,6, Okayama T7,8, Oka K9, Ideno M10, Sakai F11, Kato A12, Tanabe M13, Enoki T14, Mineno J15, Naito Y16, Itoh Y17, Yoshikawa T18. 2. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. *J Transl Med.* 2015 Aug 25;13:277. doi: 10.1186/s12967-015-0632-8. 3. Pan K1, Lv L2, Zheng HX1, Zhao JJ1, Pan QZ1, Li JJ1, Weng DS1, Wang DD1, Jiang SS1, Chang AE3, Li Q3, Xia JC1. OK-432 synergizes with IFN- γ to confer dendritic cells with enhanced antitumor immunity. *Immunol Cell Biol.* 2014 Mar;92(3):263-74. doi: 10.1038/icb.2013.87. Epub 2013 Dec 3. 4. Sudo T1, Aruga A, Shimizu K, Matsushita N, Takasaki K. OK432-activated natural killer cells enhanced trastuzumab (Herceptin)-mediated antibody-dependent cellular cytotoxicity in patients with advanced cancer. *Anticancer Res.* 2006 Nov-Dec;26(6B):4327-33.

Product Use

For research and manufacturing use